Ancora Releases Letter Regarding its Strong Opposition to H.B. Fuller’s High-Risk Attempt to Acquire U.K.-Based Advanced Medical Solutions

Ancora Releases Letter Regarding its Strong Opposition to H.B. Fuller’s High-Risk Attempt to Acquire U.K.-Based Advanced Medical Solutions

Contends the Reckless Pursuit of AMS Contradicts Management’s March 26th Public Commitment to Avoid Near-Term Deals in Favor of Necessary Deleveraging

Highlights the Potential Acquisition Would Increase Leverage to Above 4.0x Net Debt / Proforma Adjusted EBITDA and Exacerbate the Company’s Depressed Valuation Multiple

Notes Management Lacks Experience Successfully Integrating Transformative Acquisitions Involving New Product Categories with Regulatory Complexities in Foreign Geographies

Urges H.B. Fuller’s Board to Abandon its Irresponsible Pursuit of AMS and Conduct a Full Review of Strategic Alternatives, Including Evaluating Sale Options Following Apparent Buyer Interest